small molecule

TALZENNA

TALAZOPARIB TOSYLATE

Loss of exclusivityOctober 2031latest FDA-listed patent expiry

CompanyPfizer →View the full company profile on CliffBio

Drug detail

Brand name	TALZENNA
Active ingredient	TALAZOPARIB TOSYLATE
Strength	EQ 0.1MG BASE
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	June 2023
Marketing status	DISCN

Listed patents

Patent	Expires	Type
10189837	October 2031	substance, product
8735392	October 2031	substance, product
9820985	July 2029	use U-2437
10780088	July 2029	use U-3651
8012976	July 2029	substance, product
8420650	July 2029	substance, product

Regulatory exclusivity

Code	Expires
I-920	June 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Pfizer